These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11837809)

  • 1. Biological evolution of renal osteodystrophy after decreasing dialysate calcium from 1.75 to 1.6 mmol/l.
    Jean G; Chazot C; Charra B
    Clin Nephrol; 2002 Jan; 57(1):91-2. PubMed ID: 11837809
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal osteodystrophy in children with end-stage kidney failure.
    Chan JC
    Va Med; 1979 May; 106(5):384-90. PubMed ID: 463255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
    Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
    Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of keto acid (KA) treatment on renal osteodystrophy.
    Lindenau K; Kokot F; Vetter K; Schmicker R; Fröhling PT
    Infusionsther Klin Ernahr; 1987 Oct; 14 Suppl 5():40-2. PubMed ID: 3501767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of treatment with 1.25 and 1.75 mmol/l calcium dialysate on bone mineral density in haemodialysis patients.
    Van der Niepen P; Sennesael J; Louis O; Verbeelen D
    Nephrol Dial Transplant; 1995 Dec; 10(12):2253-8. PubMed ID: 8808221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vitamin A status of patients with chronic renal failure in relation to renal osteodystrophy].
    Stein G; Abendroth K; Kokot F; Keil E; Schöne S; Wessel G; Fünfstück R; Sperschneider H
    Z Urol Nephrol; 1985 Mar; 78(3):159-65. PubMed ID: 4002896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on calcium-regulating hormone in patients on chronic hemodialysis with special reference to renal osteodystrophy (ROD) (author's transl)].
    Kudo S
    Nihon Jinzo Gakkai Shi; 1982 Feb; 24(2):181-96. PubMed ID: 7098141
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
    Yaginuma T; Yamamoto H
    Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early dietary phosphorus restriction and calcium supplementation in the prevention of renal osteodystrophy.
    Maschio G; Tessitore N; D'Angelo A; Bonucci E; Lupo A; Valvo E; Loschiavo C; Fabris A; Morachiello P; Previato G; Fiaschi E
    Am J Clin Nutr; 1980 Jul; 33(7):1546-54. PubMed ID: 7395775
    [No Abstract]   [Full Text] [Related]  

  • 10. [Correlations between osteodensitometry and parameters of uremic osteodystrophy].
    Sforzini S; Viganò MR; Beretta P; Rosa M; d'Amico P; Lomuscio G; Paesani R
    Minerva Med; 1985 Mar; 76(9-10):445-8. PubMed ID: 3982703
    [No Abstract]   [Full Text] [Related]  

  • 11. Parathyroid hormone and biochemical profile in chronic kidney disease patients in South India.
    Sankarasubbaiyan S; Abraham G; Soundararajan P; Chandrasekaran V; Padma G
    Hemodial Int; 2005 Jan; 9(1):63-7. PubMed ID: 16191055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
    Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
    Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of cimetidine on serum immunoreactive parathyroid hormone in primary hyperparathyroidism and in chronic hemodialysis patients.
    Lai YH; Tsai JH; Su YH; Torng JK; Huang TJ
    Taiwan Yi Xue Hui Za Zhi; 1983 Dec; 82(12):1216-22. PubMed ID: 6585468
    [No Abstract]   [Full Text] [Related]  

  • 14. Target levels for serum phosphorus and parathyroid hormone.
    Qunibi W; Kalantar-Zadeh K
    Semin Dial; 2011; 24(1):29-33. PubMed ID: 21324001
    [No Abstract]   [Full Text] [Related]  

  • 15. Osteodystrophy of dialysed patients treated with vitamin D.
    Verberckmoes R; Bouillon R; Krempien B
    Proc Eur Dial Transplant Assoc; 1973; 10(0):217-26. PubMed ID: 4370246
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis.
    Cassidy MJ; Owen JP; Ellis HA; Dewar J; Robinson CJ; Wilkinson R; Ward MK; Kerr DN
    Q J Med; 1985 Jan; 54(213):29-48. PubMed ID: 3975345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-calcium dialysate worsens secondary hyperparathyroidism.
    Argilés A; Mion CM
    J Am Soc Nephrol; 1996 Apr; 7(4):635-6. PubMed ID: 8724901
    [No Abstract]   [Full Text] [Related]  

  • 18. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure.
    Coen G; Mazzaferro S; Ballanti P; Bonucci E
    J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330
    [No Abstract]   [Full Text] [Related]  

  • 19. Parathyroid hormone during maintenance dialysis: influence of low calcium dialysate, plasma albumin and age.
    Heaf JG; Løkkegård H
    J Nephrol; 1998; 11(4):203-10. PubMed ID: 9702872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease.
    Coen G; Bonucci E; Ballanti P; Balducci A; Calabria S; Nicolai GA; Fischer MS; Lifrieri F; Manni M; Morosetti M; Moscaritolo E; Sardella D
    Am J Kidney Dis; 2002 Aug; 40(2):348-54. PubMed ID: 12148108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.